Volenrelaxin
| Clinical data | |
|---|---|
| Other names | LY3540378 |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| UNII | |
| KEGG | |
Volenrelaxin (LY3540378) is a long-acting, synthetic analogue of relaxin developed by Eli Lilly and Company to treat heart failure.[1][2]
References
[edit]- ^ Almeida-Pinto, Nísia; Dschietzig, Thomas Bernd; Brás-Silva, Carmen; Adão, Rui (18 September 2023). "Cardiovascular effects of relaxin-2: therapeutic potential and future perspectives". Clinical Research in Cardiology. doi:10.1007/s00392-023-02305-1. hdl:10216/150307. PMID 37721595.
- ^ Verdino, Petra; Lee, Stacey L.; Cooper, Fariba N.; Cottle, Steven R.; Grealish, Patrick F.; Hu, Charlie C.; Meyer, Catalina M.; Lin, Joanne; Copeland, Victoria; Porter, Gina; Schroeder, Richard L.; Thompson, Tyran D.; Porras, Leah L.; Dey, Asim; Zhang, Hong Y.; Beebe, Emily C.; Matkovich, Scot J.; Coskun, Tamer; Balciunas, Aldona M.; Ferrante, Andrea; Siegel, Robert; Malherbe, Laurent; Bivi, Nicoletta; Paavola, Chad D.; Hansen, Ryan J.; Abernathy, Matthew M.; Nwosu, Sylvia O.; Carr, Molly C.; Heuer, Josef G.; Wang, Xiaojun (August 2023). "Development of a long‐acting relaxin analogue, LY3540378, for treatment of chronic heart failure". British Journal of Pharmacology. 180 (15): 1965–1980. doi:10.1111/bph.16055. PMID 36780899.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |